News and Announcements
Prescient Therapeutics PTX-200 Breast Cancer Trial Progresses
- Published February 18, 2016 10:16AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
17th February 2016, ASX announcement
PTX-200 Breast Cancer Trial Progress
- Phase Ib breast cancer trial enters expansion cohort
- H.Lee Moffitt Cancer Center joins trial recruitment
Melbourne, Australia 17 February 2016: Clinical stage oncology company Prescient Therapeutics Ltd (PTX) is pleased to announce that the last patient (patient 17) has been dosed in the escalation stage of its Akt inhibition Phase Ib breast cancer trial at Montefiore Cancer Center of Albert Einstein University in New York (Albert Einstein University) under the guidance of Professor Joseph Sparano. The trial is targeting women with metastatic and locally advanced HER2 negative breast cancer.
This latest patient received treatment on the third dose level and had no dose limiting toxicity (DLT). As a result, the recommended Phase II dose (RPTD) for this trial has been determined as 35 mg/m2 PTX-200, together with chemotherapy.
As part of this expansion stage, PTX is pleased to announce that the H.Lee Moffitt Cancer Center (Moffitt) in Tampa, Florida will shortly join Albert Einstein University in the Phase Ib expansion cohort and the Phase II trial, and is expected to soon commence recruitment.
Dr. Heather Han, a medical oncologist specializing in breast cancer in the Center for Women’s Oncology at Moffitt, will conduct the study.
To read the full announcement, please click here.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
